Initial insights into the interaction of antibodies radiolabeled with Lutetium-177 and Actinium-225 with tumor microenvironment in experimental human and canine osteosarcoma.
Sabeena GiriKevin J H AllenChandra Bose PrabaharanJonathan Bonet RamirezLuciano FioreMaruti UppalapatiEkaterina DadachovaPublished in: Nuclear medicine and biology (2024)
These findings suggest that radiolabeled antibodies offer a hopeful avenue for personalized OS treatment, emphasizing the importance of understanding their impact on the TME and potential synergies with immunotherapy.